Literature DB >> 24830404

Pitfalls of intranasal naloxone.

Matthew Zuckerman, Stacy N Weisberg, Edward W Boyer.   

Abstract

We present a case of failed prehospital treatment of fentanyl induced apnea with intranasal (IN) naloxone. While IN administration of naloxone is becoming more common in both lay and pre-hospital settings, older EMS protocols utilized intravenous (IV) administration. Longer-acting, higher potency opioids, such as fentanyl, may not be as easily reversed as heroin, and studies evaluating IN administration in this population are lacking. In order to contribute to our understanding of the strengths and limitations of IN administration of naloxone, we present a case where it failed to restore ventilation. We also describe peer reviewed literature that supports the use of IV naloxone following heroin overdose and explore possible limitations of generalizing this literature to opioids other than heroin and to IN routes of administration.

Entities:  

Keywords:  intranasal naloxone; overdose; prescription opioids

Mesh:

Substances:

Year:  2014        PMID: 24830404      PMCID: PMC4863654          DOI: 10.3109/10903127.2014.896961

Source DB:  PubMed          Journal:  Prehosp Emerg Care        ISSN: 1090-3127            Impact factor:   3.077


  25 in total

1.  Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes.

Authors:  K Dettmer; B Saunders; J Strang
Journal:  BMJ       Date:  2001-04-14

2.  Pharmaceutical overdose deaths, United States, 2010.

Authors:  Christopher M Jones; Karin A Mack; Leonard J Paulozzi
Journal:  JAMA       Date:  2013-02-20       Impact factor: 56.272

3.  No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose.

Authors:  David A Wampler; D Kimberley Molina; John McManus; Philip Laws; Craig A Manifold
Journal:  Prehosp Emerg Care       Date:  2011 Jul-Sep       Impact factor: 3.077

4.  Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting.

Authors:  Erik D Barton; Christopher B Colwell; Timothy Wolfe; Dave Fosnocht; Craig Gravitz; Tamara Bryan; Will Dunn; Jeff Benson; Jeff Bailey
Journal:  J Emerg Med       Date:  2005-10       Impact factor: 1.484

5.  Causes of death in injection-drug users.

Authors:  G E Woody; D S Metzger
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

6.  Whole fentanyl patch ingestion: a multi-center case series.

Authors:  Rita Mrvos; Alexander C Feuchter; Kenneth D Katz; Lynn F Duback-Morris; Daniel E Brooks; Edward P Krenzelok
Journal:  J Emerg Med       Date:  2011-06-16       Impact factor: 1.484

7.  CDC grand rounds: prescription drug overdoses - a U.S. epidemic.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-01-13       Impact factor: 17.586

Review 8.  Opioid epidemic in the United States.

Authors:  Laxmaiah Manchikanti; Standiford Helm; Bert Fellows; Jeffrey W Janata; Vidyasagar Pampati; Jay S Grider; Mark V Boswell
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

Review 9.  Management of opioid analgesic overdose.

Authors:  Edward W Boyer
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

10.  Opiate users' knowledge about overdose prevention and naloxone in New York City: a focus group study.

Authors:  Nancy Worthington; Tinka Markham Piper; Sandro Galea; David Rosenthal
Journal:  Harm Reduct J       Date:  2006-07-05
View more
  13 in total

Review 1.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

2.  Pharmacokinetics of a new, nasal formulation of naloxone.

Authors:  Ida Tylleskar; Arne Kristian Skulberg; Turid Nilsen; Sissel Skarra; Phatsawee Jansook; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2017-01-31       Impact factor: 2.953

Review 3.  Flumazenil, naloxone and the 'coma cocktail'.

Authors:  Marco L A Sivilotti
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

4.  Naloxone perspectives from people who use opioids: Findings from an ethnographic study in three states.

Authors:  Miriam Boeri; Aukje K Lamonica
Journal:  J Am Assoc Nurse Pract       Date:  2020-04-01       Impact factor: 1.165

5.  Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing.

Authors:  Mark Faul; Peter Lurie; Jeremiah M Kinsman; Michael W Dailey; Charmaine Crabaugh; Scott M Sasser
Journal:  Prehosp Emerg Care       Date:  2017-05-08       Impact factor: 3.077

6.  Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning.

Authors:  Andrew J Kassick; Mariah Wu; Diego Luengas; Mohammad Ebqa'ai; L P Tharika Nirmani; Nestor Tomycz; Toby L Nelson; Marco Pravetoni; Michael D Raleigh; Saadyah Averick
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-26

7.  Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception.

Authors:  Phillip A Saccone; Angela M Lindsey; Robert A Koeppe; Kathy A Zelenock; Xia Shao; Phillip Sherman; Carole A Quesada; James H Woods; Peter J H Scott
Journal:  J Pharmacol Exp Ther       Date:  2016-09-13       Impact factor: 4.030

8.  Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone.

Authors:  Andrew J Kassick; Heather N Allen; Saigopalakrishna S Yerneni; Fathima Pary; Marina Kovaliov; Cooper Cheng; Marco Pravetoni; Nestor D Tomycz; Donald M Whiting; Toby L Nelson; Michael Feasel; Phil G Campbell; Benedict Kolber; Saadyah Averick
Journal:  ACS Appl Bio Mater       Date:  2019-07-25

Review 9.  Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.

Authors:  Alex S Bennett; Luther Elliott
Journal:  Transl Res       Date:  2021-03-05       Impact factor: 10.171

10.  Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies.

Authors:  B T Gufford; G R Ainslie; J R White; M E Layton; J M Padowski; G M Pollack; M F Paine
Journal:  Clin Transl Sci       Date:  2017-05-23       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.